Acorda Therapeutics (Acorda Therapeutics) Other Income (Minority Interest) : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Other Income (Minority Interest)?

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. Acorda Therapeutics's Other Income (Minority Interest) for the three months ended in Dec. 2023 was $0.0 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Acorda Therapeutics Other Income (Minority Interest) Historical Data

The historical data trend for Acorda Therapeutics's Other Income (Minority Interest) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Other Income (Minority Interest) Chart

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Minority Interest)

Get a 7-Day Free Trial

Acorda Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Income (Minority Interest)	Get a 7-Day Free Trial															-	-	-	-	-

Acorda Therapeutics Other Income (Minority Interest) Calculation

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.

Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Acorda Therapeutics (OTCPK:ACORQ) Other Income (Minority Interest) Explanation

Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Acorda Therapeutics (Acorda Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Other Income (Minority Interest)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Executives

Thomas M. Burns	director	2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen	officer: CEO and President	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser	officer: Chief Financial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff	officer: General Counsel	11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem	officer: Chief Commercial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales	officer: Interim PAO & PFO	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman	officer: Exec V Pres, Gen Cnsl & Sec	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: Exec. VP-Commercial Dvlpmnt	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence	officer: Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank	officer: Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc.	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123